In another trial, SAR425899, a dual GLP-1/glucagon co-agonist, significantly reduced fasting plasma glucose, HbA1c, and body weight in patients with T2D as well as in healthy volunteers when compared to placebo [199]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.